| Project/Area Number |
59440059
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (A)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Thoracic surgery
|
|---|
| Research Institution | Chiba University School of Medicine |
|---|
Principal Investigator |
YAMAGUCHI Yutaka Department of Surgery, Institute of Pulmonary Cancer Research, 医学部, 教授 (80009448)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
斉藤 博明 千葉大学, 医学部, 助手 (40186953)
KADOYAMA Chikabumi Department of Surgery, Institute of Pulmonary Cancer Research, 医学部, 助手 (30152763)
YAMAKAWA Hisami Department of Surgery, Institute of Pulmonary Cancer Research, 医学部, 助手 (80191211)
KIMURA Hideki Department of Surgery, Institute of Pulmonary Cancer Research, 医学部, 講師 (10161572)
FUJISAWA Takehiko Department of Surgery, Institute of Pulmonary Cancer Research, 医学部, 助教授 (80110328)
SAITO Hiroaki Department of Surgery, Institute of Pulmonary Cancer Research
|
|---|
| Project Period (FY) |
1984 – 1986
|
| Project Status |
Completed (Fiscal Year 1986)
|
| Budget Amount *help |
¥11,500,000 (Direct Cost: ¥11,500,000)
Fiscal Year 1986: ¥2,000,000 (Direct Cost: ¥2,000,000)
Fiscal Year 1985: ¥3,000,000 (Direct Cost: ¥3,000,000)
Fiscal Year 1984: ¥6,500,000 (Direct Cost: ¥6,500,000)
|
|---|
| Keywords | Primary lung cancers / Anti-cancer drug in vitro sensitivity / Interleukin 2 / LAK cells / Concomitant immunity / Nd-YAG laser / Airway dilatation / 集学的治療 / 肺非小細胞癌 / 化学療法 / 免疫療法 / モノクローナル抗体 / IL2 / 腫瘍隨伴免疫 / 所属リンパ節 |
|---|
| Research Abstract |
The objective of this study is to improve the survival of patients with non-small cell lungs carcinoma by means of the multi-modality treatment including anti-cancer drug in vitro sensitivity test, neoadjuvant chemotherapy, induction of lymphokine activated Killer cells and its clinical application, endoscopic Nd-YAG laser and intratumoral ethanol injection, in particular. The materials consist of a total of 253 cases with primary non-small cell carcinomas admitted in our department during 1984 to 1986 and the results obtained herein are as follows:
1) Anti-cancer in vitro sensitivity test we performed is fulfilled with 12 hours and technically simple, and 29 of 35 experiments demonstrated positive results, indicating the possibility of clinicl applications. Neoadjuvant chemotherapy with CDDp and vindesine was effective to some cases with poorly differentiated adenocarcinoma and large cell carcinoma.
2) Interleukin 2 could induce strong killer activity against not only allogeneic but also autologous tumor cells. Moreover, there existed suppressor cells in regional lymphnode with <N_2> disease. There results demonstrates the establishment and breakdown of defense mechanism against primary lung cancers in regional lymphnode.
3) Nd-YAG laser and intratumoral ethanol injection under flexible bronchofiberscope are very effective to intraluminal protruding type of tumor, but not to compressed type.
In conclusion, Multi-modality treatment for primary non-small cell carcinomas is not uniformed, but should be consisted of effective or possibly effective treatments appropriately under the full understanding of not only tumor factors but also host factors.
|
